



21 July 2020

Mr Dean Litis  
Principal Adviser, Listings Compliance (Melbourne)  
ASX Compliance Pty Limited  
Level 4, North Tower, Rialto,  
525 Collins St, Melbourne VIC 3000

By email [dean.litis@asx.com.au](mailto:dean.litis@asx.com.au)  
[ListingsComplianceMelbourne@asx.com.au](mailto:ListingsComplianceMelbourne@asx.com.au)

Dear Dean

**DOTZ NANO LIMITED (“DTZ”) – PRICE QUERY**

We refer to your letter dated 20 July 2020 and respond as follows:

1. *Is DTZ aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?*

Yes.

2. *If the answer to question 1 is “yes”.*

- a. *Is DTZ relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in DTZ’s securities would suggest to ASX that such information may have ceased to be confidential and therefore DTZ may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is “yes”, you need to contact us immediately to discuss the situation.*

DTZ is not relying on Listing Rule 3.1A.

DTZ has been liaising with ASX in relation to a potential announcement regarding the ability of its fluorescent-based technology to detect viruses in the field, in real time, using individual DNA. DTZ has filed a Patent application on methods and conjugates for rapid and real-time detection of viruses, and is now undertaking further testing of the application of this technology in relation to COVID-19. To enable further development of this unique DTZ technology, a letter of intent for a Technology Collaboration Agreement has been signed with Brazilian genetic and health company FullDNA to provide insights on protein architecture and analysis of trial results. In addition, to facilitate clinical testing on confirmed COVID-19 patients, a Letter of Intent has been signed with the highly regarded Sheba Medical Centre in Israel.

In addition, DTZ has also recently signed a pilot agreement with Zohar-Dalia Cooperative Agricultural Association Ltd for use of Validotz™ markers in disinfectant materials to verify surface coverage for signs of any virus, including COVID-19 (“Pilot”). DTZ will receive a nominal fee for the Pilot. Zohar Dalia is Israel's largest, most advanced manufacturer, supplier, and developer of detergent intermediates and cleaning



products. Under the agreement, DTZ will mark 1,000 litres of Zohar Dalia disinfectant material to trace and verify proper surface coverage in local hospitals and other public areas. There is the potential to implement the solution in hotels, public transportation, and any public spaces requiring verified disinfection, during and post COVID-19.

DTZ also notes recent Government directives, including the Victorian State Government, requiring the compulsory wearing of face masks outside of peoples' homes. These directives will drive greater demand from consumers for authentic face masks. On 12 May 2020, DTZ announced the A\$1.5 million commercial agreement to mark 100 million medical face masks with a distributor who has customers in UK, South Africa and Australia. Since then, and with increasing Government directives of people to wear face masks, DTZ has experienced an increase in inbound enquiry from mask makers and other corporates in relation to its Validotz™ technology. DTZ continues to offer mask authentication world wide and has had ongoing discussions with manufacturers and agents across multiple geographies.

- b. *Can an announcement be made immediately? Please note, if the answer to this question is “no”, you need to contact us immediately to discuss requesting a trading halt (see below).*

DTZ has informed the market of the information above via this response, so does not believe a separate announcement needs to be made.

- c. *If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?*

N/A.

3. *If the answer to question 1 is “no”, is there any other explanation that DTZ may have for the recent trading in its securities?*

N/A

4. *Is DTZ still proposing to conduct a capital raising in July as referred to in paragraph C above?*

The Company is not proposing to conduct a capital raising in July. DTZ is currently considering various sources of funding, which could include a capital raising at a later date, reflecting the Company's forward cash flow requirements to fulfil orders and undertake additional growth initiatives.

5. *Has DTZ received the 1st \$500,000 Tranche of the \$1 million Deferred Share Placement referred to in paragraph D above? If the answer to this question is ‘No’:*

Yes.

- 5- 1. *Does DTZ still expect to receive the 1st \$500,000 Tranche?*

Final payment of Tranche 1 was received on 17 June 2020.

- 5- 2. *When does DTZ expect receive the 1st \$500,000 Tranche?*

N/A – Tranche 2 is due for payment on 1 August 2020.

*If the answer to question 5 is 'yes':*

5- 3. *When did DTZ receive the 1st \$500,000 Tranche?*

The 1st \$500,000 Tranche was received across May and June 2020, with the amount transferred to DTZ in several instalments, and this was announced after the full amount was received on 17 June 2020.

5- 4. *Why has DTZ not announced on MAP that it received 1st \$500,000 Tranche?*

This was announced to the ASX on 18 June 2020 -

<https://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=02245926>.


6. *Please confirm that DTZ is complying with the Listing Rules and, in particular, Listing Rule 3.1.*

DTZ is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

7. *Please confirm that DTZ's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of DTZ with delegated authority from the board to respond to ASX on disclosure matters.*

DTZ's responses to the questions above have been authorised and approved by its Board of Directors.

Yours sincerely



**Bernie Brookes AM**

Chairman



20 July 2020

Reference: ODIN20676

Mr Ian Pamensky  
Company Secretary  
Dotz Nano Limited  
Level 14, 330 Collins Street  
Melbourne VIC 3000

By email

Dear Mr Pamensky

### **Dotz Nano Limited ('DTZ'): Price Query**

ASX refers to the following:

- A. The change in the price of DTZ's securities from a closing price of \$0.115 on Thursday 16 July 2020 to a high of \$0.165 today.
- B. The significant increase in the volume of DTZ's securities traded from 17 July 2020 to 20 July 2020.
- C. DTZ's announcement titled '*Company Presentation- Annual General Meeting- 10 June 2020*' released on ASX's Market Announcement Platform ('MAP') dated 10 June 2020 noting under the heading 'Chairman's Comments' - '*Fund raising expected July*'.
- D. DTZ's announcement titled '*Quarterly Report- 31 March 2020*' released on 30 April 2020 which, in part, stated:

#### **Capital raising**

**On 26 November 2019 the Company announced an AU\$1 million via Deferred Share Placement (DFS). The 1<sup>st</sup> A\$500,000 Tranche of this DFS was meant to have been received by the Company on 1 April 2020. The investor, SIBF has assured the Company that the delay is due to a technical regulatory issue and the funds will be transferred as agreed.**

### **Request for information**

In light of this, ASX asks DTZ to respond separately to each of the following questions and requests for information:

1. Is DTZ aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes".
  - (a) Is DTZ relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in DTZ's securities would suggest to ASX that such information may have ceased to be confidential and therefore DTZ may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
  - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).

- 
- (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is “no”, is there any other explanation that DTZ may have for the recent trading in its securities?
  4. Is DTZ still proposing to conduct a capital raising in July as referred to in paragraph C above?
  5. Has DTZ received the 1<sup>st</sup> \$500,000 Tranche of the \$1 million Deferred Share Placement referred to in paragraph D above? If the answer to this question is ‘No’:
    - 5.1 Does DTZ still expect to receive the 1<sup>st</sup> \$500,000 Tranche?
    - 5.2 When does DTZ expect receive the 1<sup>st</sup> \$500,000 Tranche?If the answer to question 5 is ‘yes’:
    - 5.3 When did DTZ receive the 1<sup>st</sup> \$500,000 Tranche?
    - 5.4 Why has DTZ not announced on MAP that it received 1<sup>st</sup> \$500,000 Tranche?
  6. Please confirm that DTZ is complying with the Listing Rules and, in particular, Listing Rule 3.1.
  7. Please confirm that DTZ’s responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of DTZ with delegated authority from the board to respond to ASX on disclosure matters.

#### **When and where to send your response**

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **9:30am AM AEST Tuesday, 21 July 2020**. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, DTZ’s obligation is to disclose the information ‘immediately’. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require DTZ to request a trading halt immediately.

Your response should be sent to me by e-mail at **ListingsComplianceMelbourne@asx.com.au**. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

#### **Trading halt**

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is “yes” and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in DTZ’s securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

---

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

### **Suspension**

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in DTZ's securities under Listing Rule 17.3.

### **Listing Rules 3.1 and 3.1A**

In responding to this letter, you should have regard to DTZ's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that DTZ's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

### **Release of correspondence between ASX and entity**

We reserve the right to release a copy of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

### **Questions**

If you have any questions in relation to the above, please do not hesitate to contact me.

Yours sincerely

---

**Dean Litis**  
Principal Adviser, Listings Compliance (Melbourne)